GlassScriptPhysician profile
Brooke D Carr
NPI 1699242347
$4,196.76
in general payments reported to CMS, 2019-2025
39 companies · $729 in 2025
The $729 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,094 · 2022: $626 · 2023: $1,056 · 2024: $691 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.04 |
| Education | $294.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.98 | 2021-2025 | |
| Lilly USA, LLC | $372.45 | 2021-2025 | Ebglyss, Mounjaro, Taltz |
| Abbott Laboratories | $272.08 | 2023-2025 | Freestyle Libre 3, Cardiomems |
| Astellas Pharma US INC | $249.66 | 2023 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $237.24 | 2021-2025 | |
| Pfizer INC. | $225.84 | 2021-2025 | |
| Amgen INC. | $165.07 | 2021-2022 | |
| Janssen Biotech, INC. | $132.99 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.03 | 2021-2023 | Jardiance |
| Novo Nordisk INC | $125.33 | 2021-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $103.86 | 2021-2024 | Farxiga, Breztri |
| Organon LLC | $82.48 | 2025 | Vtama |
| Amarin Pharma, INC. | $71.74 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.95 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $64.62 | 2024 | Voquezna |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.